Open-Label Extension Studies: Do They Provide Meaningful Information on the Safety of New Drugs?

By Day Richard O.   Williams Kenneth M.  

Drug Safety, Vol. 30, Iss. 2, 2007-01 ,pp. : 93-105

Adis International

Access to resources Recommend Favorite

Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age: Pooled Analysis of Two Open-Label Extension Studies

By Sand Peter K.  

Drugs & Aging, Vol. 29, Iss. 2, 2012-02 ,pp. : 119-131

Adis International

Access to resources Recommend Favorite

Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients: Patient-Reported Outcomes from Multiple Controlled and Open-Label Extension Studies

By Schiff Michael H.  

Drugs & Aging, Vol. 23, Iss. 2, 2006-01 ,pp. : 167-178

Adis International

Access to resources Recommend Favorite

Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial

By Hamilton Tiffani  

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 715-726

Adis International

Access to resources Recommend Favorite

Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination: A Phase 3, Open-Label, Extension Study

By Kipnes Mark S.  

Clinical Drug Investigation, Vol. 30, Iss. 1, 2010-01 ,pp. : 51-61

Adis International

Access to resources Recommend Favorite